Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 563 entries
View as:

Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00255710 Org: User:
Start: 07/31/02 End: - Due: -

HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia

Phase: N/A Priority: Normal
NCT ID: NCT04131413 Org: User:
Start: 09/14/20 End: 04/30/26 Due: 04/30/27

A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Virally Mediated Cancers and Liposarcoma

Phase: N/A Priority: Normal
NCT ID: NCT01537744 Org: User:
Start: 02/29/12 End: 09/30/16 Due: 09/30/17

Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00133991 Org: User:
Start: 07/31/05 End: 08/31/13 Due: 08/31/14

Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas

Phase: N/A Priority: Normal
NCT ID: NCT01088815 Org: User:
Start: 09/17/10 End: 02/17/18 Due: 02/17/19

Standard-of-Care Reduced-Intensity Conditioning (RIC) With 200 Versus 400 cGy of Total Body Irradiation (TBI) in Patients With Acute Leukemia Undergoing First Allogeneic Blood or Marrow Transplantation (BMT)

Phase: N/A Priority: Normal
NCT ID: NCT06803745 Org: User:
Start: 03/27/25 End: 09/30/30 Due: 09/30/31

A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01696877 Org: User:
Start: 01/18/13 End: 12/18/18 Due: 12/18/19

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

Phase: N/A Priority: Normal
NCT ID: NCT04363164 Org: User:
Start: 08/19/20 End: 07/31/26 Due: 07/31/27

A Phase 2 Study of Bicalutamide Plus Finasteride in Men With MRI Detectable Prostate Nodules Undergoing Active Surveillance

Phase: N/A Priority: Normal
NCT ID: NCT02146937 Org: User:
Start: 03/31/14 End: 03/31/15 Due: 03/31/16

Markers for Predicting Risk of Breast Cancer in Women of Different Races

Phase: N/A Priority: Normal
NCT ID: NCT02574546 Org: User:
Start: 01/31/17 End: 01/31/20 Due: 01/31/21

Oral HPV Infection in Young Men

Phase: N/A Priority: Normal
NCT ID: NCT00897273 Org: User:
Start: 05/31/07 End: 05/05/09 Due: 05/05/10

Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT03497377 Org: User:
Start: 05/16/16 End: 04/30/20 Due: 04/30/21

Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00278161 Org: User:
Start: 01/31/05 End: 07/31/11 Due: 07/31/12

Comparison of PSMA-based 18F-DCFPyL PET/CT to Conventional Imaging in the Evaluation of Patients With Castration-Resistant Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02856100 Org: User:
Start: 08/03/16 End: 01/31/20 Due: 01/31/21

Terameprocol in Treating Patients With Recurrent High Grade Glioma

Phase: N/A Priority: Normal
NCT ID: NCT02575794 Org: User:
Start: 05/03/18 End: 10/04/23 Due: 10/04/24

POWER-remote Weight Loss Program in Early Stage Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01871116 Org: User:
Start: 07/31/13 End: 12/31/16 Due: 12/31/17

Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT01438554 Org: User:
Start: 10/31/11 End: 08/31/18 Due: 08/31/19

Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC

Phase: N/A Priority: Normal
NCT ID: NCT03439735 Org: User:
Start: 07/20/18 End: 11/01/25 Due: 11/01/26

BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations

Phase: N/A Priority: Normal
NCT ID: NCT03914742 Org: User:
Start: 02/16/20 End: 10/31/23 Due: 10/31/24

Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02420977 Org: User:
Start: 12/06/18 End: 03/01/25 Due: 03/01/26

A Window of Opportunity Study to Investigate Mechanisms of Actions of Novel Therapeutic Agents in Patients With Resectable Solid Tumor Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT03471286 Org: User:
Start: 06/06/19 End: 07/30/21 Due: 07/30/22

Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.

Phase: N/A Priority: Normal
NCT ID: NCT01928576 Org: User:
Start: 11/06/13 End: 04/04/23 Due: 04/04/24

Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma

Phase: N/A Priority: Normal
NCT ID: NCT05083754 Org: User:
Start: 08/31/22 End: 01/31/27 Due: 01/31/28

REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03610711 Org: User:
Start: 03/06/19 End: 12/31/25 Due: 12/31/26

Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant

Phase: N/A Priority: Normal
NCT ID: NCT00238368 Org: User:
Start: 02/29/04 End: 09/17/07 Due: 09/17/08